|
Novartis reports erenumab met all primary and secondary endpoints in unique Phase IIIb study in episodic migraine patients who have failed multiple prior preventive treatments
|
22 January 2018 |
|
Sandoz announces exclusive global collaboration with Biocon on next-generation biosimilars
|
18 January 2018 |
|
Sandoz regulatory submission for proposed biosimilar adalimumab accepted by FDA
|
16 January 2018 |
|
Novartis appoints Elizabeth Barrett as Oncology Head
|
11 January 2018 |
|
Novartis advances head-to-head superiority trials of Cosentyx® versus Humira®* and proposed biosimilar adalimumab**
|
09 January 2018 |
|
Novartis Kisqali® received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2- advanced breast cancer
|
03 January 2018 |
|
Novartis drug crizanlizumab shown to prolong time to patients' first sickle cell pain crisis in subgroup analysis of SUSTAIN study
|
12 December 2017 |
|
Novartis tender offer for Advanced Accelerator Applications commences
|
07 December 2017 |
|
Novartis announces Phase III STRIVE data published in NEJM demonstrating significant and sustained efficacy of erenumab (AMG334) in migraine prevention
|
29 November 2017 |
|
Novartis' Ultibro® Breezhaler® significantly improved COPD patients' lung function after direct switch from Seretide®
|
27 November 2017 |